FY2017 EPS Estimates for Pieris Pharmaceuticals, Inc. Lowered by Oppenheimer Holdings (PIRS)
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) – Equities researchers at Oppenheimer Holdings lowered their FY2017 earnings estimates for shares of Pieris Pharmaceuticals in a research note issued to investors on Thursday. Oppenheimer Holdings analyst H. Singh now anticipates that the biotechnology company will post earnings per share of ($0.84) for the year, down from their previous forecast of ($0.82). Oppenheimer Holdings also issued estimates for Pieris Pharmaceuticals’ Q1 2018 earnings at ($0.23) EPS, Q2 2018 earnings at ($0.22) EPS, Q4 2018 earnings at ($0.21) EPS, FY2018 earnings at ($0.86) EPS, FY2019 earnings at ($0.90) EPS and FY2020 earnings at ($0.88) EPS.
ILLEGAL ACTIVITY NOTICE: “FY2017 EPS Estimates for Pieris Pharmaceuticals, Inc. Lowered by Oppenheimer Holdings (PIRS)” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/08/22/fy2017-eps-estimates-for-pieris-pharmaceuticals-inc-lowered-by-oppenheimer-holdings-pirs.html.
A number of other brokerages have also issued reports on PIRS. BidaskClub lowered shares of Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 26th. HC Wainwright set a $9.00 price objective on shares of Pieris Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 11th. Rodman & Renshaw began coverage on shares of Pieris Pharmaceuticals in a report on Tuesday, May 30th. They issued a “buy” rating and a $9.00 price objective for the company. Finally, TheStreet lowered shares of Pieris Pharmaceuticals from a “c-” rating to a “d-” rating in a report on Monday, June 12th. Five equities research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and a consensus target price of $8.25.
Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) opened at 5.07 on Monday. The company’s market cap is $224.64 million. The stock has a 50 day moving average of $5.34 and a 200 day moving average of $3.71. Pieris Pharmaceuticals has a 12-month low of $1.30 and a 12-month high of $6.20.
In related news, insider Allan Reine bought 65,000 shares of the stock in a transaction on Thursday, August 17th. The stock was bought at an average price of $4.82 per share, with a total value of $313,300.00. Following the completion of the purchase, the insider now directly owns 45,000 shares in the company, valued at approximately $216,900. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director James A. Geraghty bought 10,000 shares of the stock in a transaction on Thursday, August 17th. The shares were bought at an average cost of $4.82 per share, with a total value of $48,200.00. Following the purchase, the director now owns 10,000 shares of the company’s stock, valued at $48,200. The disclosure for this purchase can be found here. Company insiders own 4.05% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in PIRS. Voya Investment Management LLC bought a new position in shares of Pieris Pharmaceuticals during the second quarter valued at $100,000. State of Wisconsin Investment Board bought a new position in shares of Pieris Pharmaceuticals during the second quarter valued at $132,000. Creative Planning raised its position in shares of Pieris Pharmaceuticals by 29.6% in the first quarter. Creative Planning now owns 60,000 shares of the biotechnology company’s stock valued at $156,000 after buying an additional 13,700 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of Pieris Pharmaceuticals by 1,106.3% in the second quarter. The Manufacturers Life Insurance Company now owns 31,785 shares of the biotechnology company’s stock valued at $161,000 after buying an additional 29,150 shares during the period. Finally, Acadian Asset Management LLC bought a new position in shares of Pieris Pharmaceuticals during the second quarter valued at $162,000. 45.34% of the stock is owned by institutional investors.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Stock Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.